Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Expenses: 2019-2024

Historic Operating Expenses for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to $201.1 million.

  • Centessa Pharmaceuticals' Operating Expenses rose 15.91% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.8 million, marking a year-over-year increase of 35.78%. This contributed to the annual value of $201.1 million for FY2024, which is 12.87% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Operating Expenses stood at $201.1 million for FY2024, which was up 12.87% from $178.1 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Operating Expenses registered a high of $210.3 million during FY2022, and its lowest value of $10.4 million during FY2020.
  • For the 3-year period, Centessa Pharmaceuticals' Operating Expenses averaged around $196.5 million, with its median value being $201.1 million (2024).
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Operating Expenses surged by 1,227.09% in 2021, and later decreased by 15.29% in 2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Operating Expenses (Yearly) stood at $10.4 million in 2020, then surged by 1,227.09% to $138.5 million in 2021, then skyrocketed by 51.78% to $210.3 million in 2022, then fell by 15.29% to $178.1 million in 2023, then increased by 12.87% to $201.1 million in 2024.